Asset 2 Conferences
Schmidt Andreas - profile page

Andreas Schmidt

CEO, Proteona, DE

Dr Andreas Schmidt is the CEO of Proteona, a venture capital backed biomedical company combining both genomic and proteomic data for single cell analysis. The interaction of individual cells determines the function of the human body and the state of any disease. Using an artificial intelligence approach Proteona sheds new light on the interaction of mRNA and proteins in thousands of cells in every clinical sample enabling new insights into clinical immunoncology and making new immuncell therapies possible for the pharma community. Proteona maintains multiple commercial cooperations with multinational pharma companies as well as startups and clinical research institution. Proteona is a spin off from the lab of Prof. Gene Yeo at the National University of Singapore and the University of California at San Diego as well as the A-Star Molecular Engineering Lab of Nobel Laureate Prof. Sydney Brenner.

Previously Andreas Schmidt has co-founded AYOXXA Biosystems and headed the translational proteomics company as CEO from 2009 to 2016 continuously expanding the company to more than 40 employees operating from three sites in Cologne Germany, Singapore and Boston. He raised more than 30 Mil USD in venture capital, built the overall strategy of the company and established partnerships with several multinational pharma companies and leading academic institutions in the US, Asia and Europe. This includes for example the Horizont 2020 Eye-Risk consortium on Age Related Macular Degeneration with Roche and multiple clinical centers.

Dr Schmidt is board member, advisor and mentor for several biomedical companies and entrepreneurs, often with an Asia oriented business strategy. He serves as Catalyst for the SMART Singapore MIT Alliance of Research and Technology as well as investment committee member of the equity crowd health investment platform Aescuvest in conjunction with the European Institute of Innovation & Technology EIT. Andreas Schmidt obtained a PhD in molecular and cell biology jointly from the University of Cologne Germany and the University of California, Berkeley. He received several prestigious fellowships, awards and entrepreneurship recognitions in the USA, Germany, Taiwan and Singapore.

Speaker at